ContraFect to Present at the 2019 Janney Healthcare Conference
September 04 2019 - 5:07PM
ContraFect Corporation
(Nasdaq:CFRX), a clinical-stage biotechnology
company focused on the discovery and development of direct lytic
agents (DLAs), including lysins and amurin peptides, as a new
modality for the treatment of life-threatening,
antibiotic-resistant infections, today announced that Roger J.
Pomerantz, MD, Chairman and Chief Executive Officer, will present
at the 2019 Janney Montgomery Scott Healthcare Conference on
Tuesday, September 10, 2019, at 9:05 a.m. ET in New York City. The
focus will be on exebacase (CF-301), the Company's novel
therapeutic candidate for Staph aureus bacteremia, including
endocarditis, along with an update on the progress of its other
pipeline assets.
A live webcast of the presentation will be
available on the Investors & Media section of the Company’s
website at www.contrafect.com. The presentation will also be
available as an archived webcast for a limited time.
About ContraFect:
ContraFect is a biotechnology company focused on
discovering and developing differentiated biologic therapies for
life-threatening, drug-resistant infectious diseases, particularly
those treated in hospital settings. An estimated 700,000 deaths
worldwide each year are attributed to antimicrobial-resistant
infections. We intend to address life threatening infections using
our therapeutic product candidates from our platform of direct
lytic agents (DLAs), which include lysins and amurin peptides.
Lysins are a new class of DLAs which are recombinantly produced,
antimicrobial proteins with a novel mechanism of action associated
with the rapid killing of target bacteria, eradication of biofilms
and synergy with conventional antibiotics. Amurin peptides are new
class of DLAs which exhibit broad-spectrum activity against a wide
range of antibiotic-resistant Gram-negative pathogens, including
Pseudomonas aeruginosa (P. aeruginosa), Acinetobacter baumannii,
and Enterobacter species. We believe that the properties of our
lysins and amurin peptides will make them suitable for targeting
antibiotic-resistant organisms, such as methicillin-resistant Staph
aureus (MRSA) and P. aeruginosa, which can cause serious infections
such as bacteremia, pneumonia and osteomyelitis. We have completed
a Phase 2 clinical trial for the treatment of Staph aureus
bacteremia, including endocarditis, with our lead lysin candidate,
exebacase (CF-301), which is the first lysin to enter clinical
studies in the U.S.
Follow ContraFect on Twitter @ContraFectCorp and
LinkedIn.
Forward-Looking Statements:
This press release contains, and our officers
and representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding the Company’s
ability to discover and develop DLAs as new modalities for the
treatment of life-threatening, antibiotic-resistant infections, the
planned presentation, the Company’s ability to address life
threatening infections using its therapeutic product candidates
from its DLA platform, whether lysins are a new class of DLAs
which are recombinantly produced, antimicrobial proteins with a
novel mechanism of action associated with the rapid killing of
target bacteria, eradication of biofilms and synergy with
conventional antibiotics, whether amurins exhibit broad-spectrum
activity against a wide range of antibiotic-resistant Gram-negative
pathogens, and whether the properties of the Company’s lysins and
amurins will make them suitable for targeting antibiotic-resistant
organisms, such as Staph aureus and P. aeruginosa.. Forward-looking
statements are statements that are not historical facts, nor
assurances of future performance. Instead, they are based on
ContraFect’s current beliefs, expectations and assumptions
regarding the future of its business, future plans, strategies,
projections, anticipated events and trends, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent risks, uncertainties and
changes in circumstances that are difficult to predict and many of
which are beyond ContraFect’s control, including those detailed
under the caption “Risk Factors” in ContraFect's filings with the
Securities and Exchange Commission. Actual results may differ
from those set forth in the forward-looking statements. Important
factors that could cause actual results to differ include, among
others, our ability to develop treatments for drug-resistant
infectious diseases. Any forward-looking statement made by
ContraFect in this press release is based only on information
currently available and speaks only as of the date on which it is
made. Except as required by applicable law, ContraFect expressly
disclaims any obligations to publicly update any forward-looking
statements, whether written or oral, that may be made from time to
time, whether as a result of new information, future developments
or otherwise.
Investor Relations Contacts:
Michael MessingerContraFect CorporationTel: 914-207-2300Email:
mmessinger@contrafect.com
Lauren StivalStern Investor RelationsTel: 212-362-1200Email:
lauren.stival@sternir.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Sep 2023 to Sep 2024